Beth McQuiston

USPTO Granted Patents = 17 (Patent Applications = 26)

EPO Patents = 5 (Patent Applications = 20)

Average Co-Inventor Count = 4.3

ph-index = 6

Forward Citations = 41(Granted Patents)

Company Filing History:

17 out of 4,179

Abbott Laboratories Corporation

patents

1 out of 597

Cedars-sinai Medical Center

patents

where one patent can have more than one assignee

Years Active: 2020-2024

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12178592 - Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I (2024-12-31),

2. 12163958 - Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1 (2024-12-10),

3. 12105100 - Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 (2024-10-01),

4. 12105098 - Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) (2024-10-01),

5. 12099069 - Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers (2024-09-24),

6. 12092647 - Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers (2024-09-17),

7. 12085567 - Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject (2024-09-10),

8. 11994523 - Biomarkers and methods for diagnosing and evaluating traumatic brain injury (2024-05-28),

9. 11931161 - Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers (2024-03-19),

10. 11129564 - Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I (2021-09-28),

11. 11022617 - Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) (2021-06-01),

12. 11016105 - Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 (2021-05-25),

13. 11016092 - Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1 (2021-05-25),

14. 10877048 - Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers (2020-12-29),

15. 10877038 - Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject (2020-12-29),

Title: The Innovative Mind of Beth McQuiston

Introduction

Beth McQuiston is an accomplished inventor based in Abbott Park, Illinois, who has made significant strides in the medical field. With a remarkable portfolio of 17 patents, her work focuses on diagnosing and evaluating traumatic brain injuries through innovative methodologies. Her contributions have potential implications for improving patient outcomes in emergency medical situations.

Latest Patents

Among her latest patents is a groundbreaking method for aiding in the diagnosis and evaluation of mild traumatic brain injuries (TBI) in human subjects using cardiac troponin I (cTnI). This patent discloses innovative techniques that assist in determining whether a computerized tomography (CT) scan is necessary by detecting levels of cTnI. Additionally, she has developed methods utilizing the biomarker ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) for assessing the extent of TBIs. These methods allow for the detection of UCH-L1 levels within 24 hours of injury, potentially guiding critical medical decisions.

Career Highlights

Beth McQuiston has had a distinguished career, having worked with leading organizations such as Abbott Laboratories and Cedars-Sinai Medical Center. Her experience in these institutions has provided her with a platform to innovate and advance her research in traumatic brain injuries.

Collaborations

Throughout her career, McQuiston has collaborated with talented professionals, including Saul A. Datwyler and Jaime Marino. These partnerships have fostered a productive environment for developing innovative solutions to complex medical challenges.

Conclusion

In summary, Beth McQuiston's impactful work as an inventor continues to advance the understanding and treatment of traumatic brain injuries. With her numerous patents, innovative methodologies, and collaborative efforts, she is making a significant difference in the medical field, contributing to the future of patient care and emergency medicine.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com